Stifel raised the firm’s price target on Idexx Laboratories (IDXX) to $460 from $420 and keeps a Hold rating on the shares. The firm says that the company’s Q1 results were not surprising, but the stock’s reaction was a bit stronger than expected. Stifel will continue to monitor the uptake of Cancer Dx and inVue, but for now the firm believes the near-term contribution is already reflected in estimates.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on IDXX:

Disclaimer & DisclosureReport an Issue

Early notable gainers among liquid option names on May 1st Idexx Laboratories: Stable Performance and Growth Potential Amid Market Challenges Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84 Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99 Is IDXX a Buy, Before Earnings?

View Comments